You are here

Cabenuva

GSK’s Injectable HIV Drug Bests Pills in Patients with Medication Adherence Issues

BioSpace

Wed, 02/21/24 - 11:17 am

ViiV Healthcare

clinical trials

GSK dials up HIV sales projection to £7B by 2026, updates next-gen launch timelines

Fierce Pharma

Thu, 09/28/23 - 10:45 am

ViiV Healthcare

J&J, GSK's ViiV tout switching study showing patients prefer their long-acting HIV med Cabenuva over Gilead rival

Fierce Pharma

Tue, 07/25/23 - 09:20 pm

Gilead Sciences

GSK's ViiV explores novel pathway to bring long-acting HIV med Cabenuva to tough-to-treat patients

Fierce Pharma

Thu, 07/6/23 - 10:07 pm

ViiV Healthcare

CROI 2023 – GSK and Gilead’s long-acting HIV battle intensifies

EP Vantage

Mon, 02/27/23 - 07:01 pm

Gilead Sciences

GSK's ViiV says study shows its long-acting HIV shot as effective as Gilead's daily pill

Yahoo/Reuters

Fri, 02/24/23 - 09:08 am

ViiV Healthcare

Gilead Sciences

With competitors circling, ViiV wins another label update for long-acting HIV injectable Cabenuva

Endpoints

Thu, 03/24/22 - 08:33 pm

ViiV Healthcare

Bottlenecks are slowing switch to GSK's long-acting HIV injectable Cabenuva: clinician

Fierce Pharma

Tue, 03/8/22 - 10:57 pm

ViiV Healthcare gets FDA nod for two-month dosing of Cabenuva to treat HIV

Pharmaceutical Business Review

Wed, 02/2/22 - 10:57 am

ViiV Healthcare

ViiV Healthcare seeks USFDA approval to expand Cabenuva use for HIV-1 infected adults

Pharmaceutical Business Review

Thu, 02/25/21 - 09:50 am

ViiV Healthcare

FDA Approvals Roundup: Cabenuva, Lupkynis, Verquvo

RAPS.org

Thu, 01/28/21 - 10:49 am

3 Blockbuster Drug Launches to Watch This Year

Motley Fool

Sun, 01/24/21 - 03:24 pm

Gilead Sciences

FDA approves first monthly injectable to treat HIV infection

Stat

Thu, 01/21/21 - 11:45 pm

GSK's ViiV touts 2-month HIV data as sister injection Cabenuva awaits FDA redemption

Fierce Pharma

Mon, 03/9/20 - 10:39 am